Author

A. Limper

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:clinical cohort / trial· 1

Frequent Co-Authors

K. Schaefbauer· 2 shared T. Kottom· 2 shared E. M. Carmona· 1 shared J. E. Yi· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

4 top collaborators · 6 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

K. Schaefbauer

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Blood Chemistry Analysis in an Active Pneumocystis Pneumonia (PCP) Model Treated with Selective CARD9 Inhibitor BRD5529

T. Kottom, K. Schaefbauer, A. Limper

This study evaluates the blood chemistry effects of BRD5529, a CARD9 inhibitor, in an active PCP mouse model, finding significant reduction in BUN levels but no other significant changes.

bioRxiv · Jul 21, 2022 · PreprintImmunology

Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9

T. Kottom, K. Schaefbauer, E. M. Carmona, J. E. Yi, A. Limper

This study evaluates the safety and toxicology of BRD5529, a CARD9 inhibitor, in mice, finding no significant adverse effects at tested doses.

bioRxiv · Nov 19, 2021Pharmacology & Toxicology